loading
BioLingus (Cayman) Ltd stock is traded at $0.00, with a volume of 0. It is up +0.00% in the last 24 hours and up +0.00% over the past month. BioLingus (Cayman) Ltd is a pioneering Swiss biotech company recognized for its groundbreaking work in advancing oral (sublingual) and mucosal delivery of peptides and proteins. Rooted in the philosophy of being 'inspired by nature' the company employs applied bio-engineering to create innovative bio-mimetic materials for drug delivery. Focused on addressing chronic diseases such as diabetes, obesity, and inflammatory conditions, BioLingus develops its own products. The main office is situated in Switzerland, with additional branches in Hong Kong and Australia. Notably, BioLingus is at the forefront of diabetes treatment, with lead molecules including an oral 'biobetter' of liraglutide and exenatide for type II diabetes, as well as a combination product of insulin and GLP1. The company is also exploring the use of low dose IL-2 for early onset juvenile type I diabetes, demonstrating promising results in animal models. In the realm of immuno-therapy, sublingual administration facilitates direct targeting of the lymphatic system, with notable success in arthritis, psoriasis, diabetes type 1, peanut allergy, and cancer. Beyond therapeutic efficacy, BioLingus' technology offers the potential to stabilize proteins and peptides, reducing the need for a cold chain and preventing infections associated with needle handling. This innovation aligns with the company's commitment to 'broaden access' for patients in third-world countries, contributing to the World Health Organization's vital goal of expanding healthcare accessibility globally.
See More
Previous Close:
$0.00
Open:
$0
24h Volume:
0
Relative Volume:
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
Value
$0.00
$0.00
1-Week Range:
Value
$0.00
$0.00
52-Week Range:
Value
$0.00
$0.00

BioLingus (Cayman) Ltd Stock (SUBL) Company Profile

Name
Name
BioLingus (Cayman) Ltd
Name
Phone
41786645430
Name
Address
GROSSMATT 6, NW HERGISWIL
Name
Employee
15
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
SUBL's Discussions on Twitter

Compare SUBL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SUBL
BioLingus (Cayman) Ltd
0.00 0 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
412.11 106.13B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
733.59 80.61B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
649.26 38.82B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
240.55 31.03B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
122.15 29.28B 3.30B -501.07M 1.03B -2.1146

BioLingus (Cayman) Ltd Stock (SUBL) Latest News

BioLingus (Cayman) Ltd Stock (SUBL) Financials Data

There is no financial data for BioLingus (Cayman) Ltd (SUBL). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$73.13
price down icon 0.08%
$22.19
price up icon 0.05%
$366.61
price up icon 1.18%
$43.17
price down icon 9.17%
biotechnology ONC
$177.88
price up icon 1.59%
$122.15
price down icon 3.73%
Cap:     |  Volume (24h):